Syngene International Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit".